Diagnostic Center | October 09, 2022
Pfizer announces positive topline results from Phase 3 TALAPRO-2 trial
Study achieves primary endpoint of radiographic progression-free survival
Study achieves primary endpoint of radiographic progression-free survival
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
This clinical study will inform operational logistics and use of AV7909 should an anthrax emergency occur.
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
Brivaracetam is indicated for the treatment of partial-onset seizures in patients 4 years of age and older.
Dr. Fesharaki most recently served as the Chief Scientific Officer and Global Head of R&D for Hikma Pharmaceuticals.
The product will be manufactured at Lupin's facility in Nagpur, India.
This acquisition will accelerate Medcare's plans to emerge as an international hub for health, beauty, and wellness adding to its existing network of 4 hospitals and over 20 medical centres in the UAE.
Specialized cancer care will be offered to cancer patients making it accessible and affordable. We have adopted a patient-centric approach.
Mirabegron is indicated for the treatment of overactive bladder (OAB) with symptoms of urinary incontinence, urgency, and frequency
Subscribe To Our Newsletter & Stay Updated
